WO2022083582A1 - 半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物作为结肠直肠癌诊断标志物的应用 - Google Patents

半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物作为结肠直肠癌诊断标志物的应用 Download PDF

Info

Publication number
WO2022083582A1
WO2022083582A1 PCT/CN2021/124691 CN2021124691W WO2022083582A1 WO 2022083582 A1 WO2022083582 A1 WO 2022083582A1 CN 2021124691 W CN2021124691 W CN 2021124691W WO 2022083582 A1 WO2022083582 A1 WO 2022083582A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
complex
cathepsin
quantitative detection
detection agent
Prior art date
Application number
PCT/CN2021/124691
Other languages
English (en)
French (fr)
Inventor
王力军
孙玉龙
杨亚云
王弢
Original Assignee
上海良润生物医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海良润生物医药科技有限公司 filed Critical 上海良润生物医药科技有限公司
Publication of WO2022083582A1 publication Critical patent/WO2022083582A1/zh

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)

Definitions

  • the present application relates to the field of medical diagnostics, in particular, to the application of a cysteine protease inhibitor SN and Cathepsin B complex as a diagnostic marker for colorectal cancer.
  • Colorectal cancer is one of the common malignant tumors in the gastrointestinal tract.
  • Tumorgenesis is a multifactorial and multistage process, and tumor invasion and metastasis include adhesion, degradation and penetration. Tumor invasion and metastasis are important characteristics of malignant tumors.
  • proteolytic enzymes play a key role in tumor invasion.
  • Proteolytic enzymes are a class of endopeptidases or exopeptidases capable of hydrolyzing or modifying the peptide bonds of proteins or polypeptides.
  • CTSB Cathepsin B
  • mammalian and human lysosomes are cysteine protease present in mammalian and human lysosomes. Recent studies have shown that abnormal expression of CTSB is often found in tumor tissues, such as gastric cancer, colon cancer, cervical cancer, lung cancer, breast cancer and prostate cancer.
  • Cystatin SN (cystatins SN, CST1) is a kind of cathepsin inhibitor. It is a protein of 141 amino acids encoded by CST1 gene with a molecular weight of 16.4kDa. The CST1 molecule contains two disulfide bonds and is a typical secreted protein. It can inhibit intracellular and extracellular cathepsin activity and play an important role in tumor growth, angiogenesis, infiltration and metastasis. High expression is associated with a variety of cancers.
  • CTSB is not only highly expressed in colorectal cancer, but also expressed in gastric cancer, glioma, melanoma and other patients, CTSB has poor tissue specificity when used as a tumor diagnostic marker, making it difficult to identify tumors. specific type.
  • CST1 also has a certain degree of discrimination in colorectal cancer, due to its high sequence homology with the same family of cysteine protease inhibitors, CST1 also has certain limitations as a colorectal cancer target . Studies have shown that CTSB is one of the main inhibitory substrates of CST1, and CTSB can be inhibited by CST1 to form a complex.
  • a quantitative detection agent of cystatin SN and Cathepsin B complex in the preparation of a kit for diagnosis, auxiliary diagnosis or prognostic analysis of colorectal cancer.
  • a quantitative detection agent for the complex of cystatin SN and Cathepsin B for the diagnosis, auxiliary diagnosis or prognostic analysis of colorectal cancer.
  • the quantitative detection agent is an antibody specific for the Cystatin SN and the Cathepsin B, and the antibody can be used to perform co-immunoprecipitation or enzyme-linked immunosorbent assay to detect all the The cysteine protease inhibitor SN and Cathepsin B complex were detected.
  • the quantitative detection agent is an antibody specific for the complex of Cystatin SN and Cathepsin B.
  • the specific antibody is a monoclonal antibody or a polyclonal antibody.
  • the specific antibody is obtained by immunization with the amino acid sequence shown in SEQ ID NO:1.
  • the specific antibody has a label for indicating signal strength.
  • the label for indicating signal strength is selected from any one or more of chromophores, digoxigenin-labeled probes, electron-dense substances, colloidal gold, or enzymes.
  • a colorectal cancer diagnostic, auxiliary diagnostic or prognostic analysis kit comprising a specific antibody as defined above.
  • the kit further comprises at least one of a solid phase carrier, a blocking solution, a chromogenic reagent, a calibrator for the fusion antigen of cystatin SN and Cathepsin B, and a washing buffer.
  • the solid support is a chemiluminescent plate.
  • a method for diagnosis, auxiliary diagnosis or prognostic analysis of colorectal cancer comprising: measuring cysteine protease using the quantitative detection agent or kit as described above The content of the inhibitor SN in complex with Cathepsin B.
  • FIG. 1 is an SDS-PAGE electrophoresis image after purification of CST1-CTSB recombinant protein in an embodiment of the application;
  • Fig. 2 is the calibration curve of CST1-CTSB detection kit in an embodiment of the application
  • FIG. 4 is the ROC curve of CST1-CTSB for colorectal cancer diagnosis in one embodiment of the present application.
  • the present application relates to the application of a quantitative detection agent of cystatin SN and Cathepsin B complex (CST1-CTSB complex) in the preparation of a kit for diagnosis, auxiliary diagnosis or prognostic analysis of colorectal cancer.
  • CST1-CTSB complex Cathepsin B complex
  • colorectal cancer Colon and rectal cancer are collectively known as colorectal cancer. Both share many similar characteristics and are therefore discussed in this application as one cancer type.
  • CST1-CTSB complex provides a new marker for diagnosis: CST1-CTSB complex.
  • CTSB can be inhibited by CST1 to form a complex, while CST4 does not have this ability. Therefore, the detection of CST1-CTSB complex can effectively improve the tissue specificity of the marker, and can also effectively improve the detection rate of early colorectal cancer.
  • the term "marker” as used herein refers to a molecule to be used as a target for analyzing a patient's experimental sample.
  • molecular targets are proteins or polypeptides.
  • Proteins or polypeptides used as markers in the present application are intended to include naturally occurring variants of said proteins as well as fragments of said proteins or said variants, particularly immunologically detectable fragments.
  • the immunologically detectable fragment comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 15, or 20 contiguous amino acids of the marker polypeptide.
  • proteins released by cells or present in the extracellular matrix may be damaged (eg, during inflammation) and may be degraded or cleaved into such fragments.
  • markers are synthesized in an inactive form, which can then be activated by proteolysis.
  • proteins or fragments thereof can also be present as part of a complex.
  • Such complexes can also be used as markers in the sense of the present application.
  • marker polypeptides or variants thereof may carry post-translational modifications.
  • Non-limiting examples of post-translational modifications are glycosylation, acylation and/or phosphorylation.
  • the marker should be located at the binding site of CST1 and CTSB in the CST1-CTSB complex. This "binding site" refers to the site where the amino acid sequences contact each other when CST1 and CTSB interact, which can be a linear epitope or a spatial epitope. bit.
  • the quantitative detection reagent is a specific antibody of the Cystatin SN and the Cathepsin B, and the antibody can be used to perform co-immunoprecipitation or enzyme-linked immunosorbent assay to detect all the The CST1-CTSB complex was detected.
  • Quantitative detection reagents can detect CST1-CTSB complexes by methods known in the art; possible methods such as biological mass spectrometry, native polyacrylamide gel electrophoresis, chromatography, enzyme-linked immunosorbent assay, immunofluorescence, Immunochemiluminescence, immunoturbidimetry, immunoblotting, and dot blot. Common methods are co-immunoprecipitation and enzyme-linked immunosorbent assay.
  • CST1 can be captured by A antibody, unbound components can be washed away, and CTSB can be detected by B antibody with signal substance; of course, CTSB can also be captured and then CST1 can be detected. , which is easy for those skilled in the art.
  • Quantitative detection reagents are usually reagents that specifically detect the CST1-CTSB complex, for example, a lectin that specifically binds to the CST1-CTSB complex, an aptamer that specifically binds to the CST1-CTSB complex, or that specifically binds to the CST1-CTSB complex Complex antibodies and antibody fragments.
  • a specific binding agent has an affinity of at least 10 7 l/mol for its corresponding target molecule. In some embodiments, a specific binding agent may have an affinity of 10 8 1/mol for its target molecule. In some embodiments, a specific binding agent may have an affinity of 10 9 1/mol for its target molecule.
  • specific means that other biomolecules present in the sample do not bind significantly to the quantitative detection agent of the CST1-CTSB complex, such biomolecules in particular being free CST1 and CTSB alone.
  • the quantitative detection agent is an antibody specific for the CST1-CTSB complex.
  • the specific antibody is a monoclonal antibody or a polyclonal antibody.
  • the specific antibody is obtained by immunization with the amino acid sequence shown in SEQ ID NO: 1.
  • the CST1-CTSB recombinant protein can be used to screen the antibody that specifically binds to the CST1-CTSB complex, and optionally an antibody with high antibody titer can be selected.
  • the specific antibody has a label for indicating signal strength.
  • the label for indicating signal strength is selected from any one or more of chromophores, digoxigenin-labeled probes, electron-dense substances, colloidal gold, or enzymes.
  • Enzymes that produce a detectable signal such as by colorimetry, fluorescence and luminescence, such as horseradish peroxidase, alkaline phosphatase, beta-galactosidase and glucose-6-phosphate dehydrogenase.
  • Chromophores such as fluorophores, quantum dots, fluorescent microspheres, luminescent compounds (eg acridinium esters or derivatives thereof) and dyes.
  • a detectable group such as its molecular size is sufficient to induce a modification detectable in its physical and/or chemical properties; such detection can be achieved by optical methods (eg diffraction, surface plasmon resonance, surface variation and contact variation angle) or Physical methods (such as atomic force spectroscopy and tunneling) are implemented.
  • optical methods eg diffraction, surface plasmon resonance, surface variation and contact variation angle
  • Physical methods such as atomic force spectroscopy and tunneling
  • Electron dense substances such as radioactive molecules (eg 32 P, 35 S or 125 I).
  • the present application also relates to a colorectal cancer diagnostic kit comprising a specific antibody as defined above.
  • the kit further comprises at least one of a solid phase carrier, a blocking solution, a color developing agent, a calibrator for the CST1-CTSB fusion antigen, and a washing buffer.
  • the calibrator of the CST1-CTSB fusion antigen preferably has the amino acid sequence shown in SEQ ID NO:1.
  • the blocking solution can be one or more of BSA, bovine serum, skim milk, TBST and other components.
  • the color developing solution can be determined according to the substance labeled on the antibody, for example, when the labeled substance is horseradish peroxidase, the color developing agent can be luminol.
  • the washing buffer can be PBS, TBS and other components.
  • the blocking solution, color developing solution, washing buffer can be packaged in the kit in the form of working concentration, or can be packaged in the form of their concentrated mother solutions (for example, 2, 3, 4, 5, 6, 7, 8, 9 , 10, 20, 30, 40, 50 times concentrated mother liquor).
  • the solid phase carrier is usually used to coat the antibody, and the solid phase carrier material used for coating the antibody can be polystyrene, cellulose, polyacrylamide, polyethylene polypropylene, cross-linked dextran, glass, silicone rubber, agar Glycogel and other materials, the carrier can be in the form of test tubes, Eppendorf tubes, multi-well plates (especially chemiluminescence plates), wells of micro-reaction plates, beads (especially magnetic beads), small discs, and the like.
  • the solid support is a chemiluminescent plate. It may contain 16, 32, 48, 64, 96 or more wells.
  • the present application also provides a method for diagnosis, auxiliary diagnosis or prognostic analysis of colorectal cancer, the method comprising: measuring CST1- Content of CTSB complex.
  • the detected sample can be at least one of blood, serum, cerebrospinal fluid, tissue or tissue lysate, semen, and saliva samples of the subject.
  • the subject is usually a mammal.
  • the subject can be a primate.
  • the subject can be a human.
  • Protein expression The gene was synthesized according to the amino acid sequence of SEQ ID NO: 1 in the sequence listing and optimized for mammalian expression codons. The gene was inserted into pcDNA3.1 vector containing 6 ⁇ His tag to obtain pcDNA3.1-CST1-CTSB. Then pcDNA3.1-CST1-CTSB was transformed into DH5 ⁇ , positive clones were picked and cultured in large quantities, and the recombinant plasmid pcDNA3.1-CST1-CTSB was extracted with a high-purity plasmid extraction kit. The recombinant plasmid was transferred into 293t cells, and at the same time, the pcDNA3.1 empty vector was transfected as a negative control. The cells were cultured in DMEM medium containing 10% fetal bovine serum at 37 °C and 5% CO 2 for 72 h, and the supernatant was collected. The supernatant was filtered using a 0.22 ⁇ m filter.
  • Protein purification The obtained 500 mL filtrate was subjected to Ni-NTA affinity chromatography under native conditions. Equilibration was performed with equilibration buffer (50 mM PBS, 10 mM imidazole, 150 mM NaCl, pH 7.6). After loading, wash with 10 mL washing buffer; elute with elution buffer (50 mM PBS, 250 mM imidazole, 150 mM NaCl, pH 7.6), and collect the eluate. The protein solution was concentrated using a 3kD ultrafiltration tube, and the protein was stored in 50mM PBS buffer (pH 7.4) at -80°C. The purity of the purified protein was identified by SDS-PAGE, the molecular weight was about 52kD, and the grayscale analysis showed that the protein purity reached more than 95% (Fig. 1).
  • Antibody pairing chemiluminescent plates were coated with 1 ⁇ g/ml capture antibody. Add 100 ⁇ l of CST1-CTSB calibrator at different concentrations (5-1000 pg/mL) to each well, incubate at 37 °C for 60 min, add 100 ⁇ L of HRP-labeled detection antibody at a concentration of 100 ng/ml to each well after washing, and incubate at 37 °C for 60 min. After washing, a chemiluminescent substrate was added and the luminescence intensity of each well was measured. From the results, the capture antibody and the detection antibody are well paired and can be used for the construction of a double-antibody sandwich system.
  • Calibration curve drawing First, the capture antibody was coated on a chemiluminescent plate overnight at 4°C at a concentration of 1 ⁇ g/mL.
  • the recombinant human CST1-CTSB calibrator protein was diluted with protein stabilizer to 0pg/mL, 10pg/mL, 50pg/mL, 100pg/mL, 200pg/mL, 500pg/mL, 1500pg/mL, and 100 ⁇ L was added to each well for incubation. , after washing, add HRP-labeled detection antibody at a concentration of 5ng/ml, 100 ⁇ L per well, and incubate at 37°C for 1 hour.
  • FIG. 1 shows the calibration curve of the CST1-CTSB detection kit.
  • the linear range of the calibration curve is 10-1500 pg/mL, wherein the Y-axis represents the logarithmic value of the luminescence value, and the X-axis represents the logarithmic concentration value of the CST1-CTSB calibrator.
  • CST1-CTSB detection kit for colorectal cancer diagnosis. Fifty preoperative sera from colorectal cancer patients were collected from the hospital; at the same time, the serum of 50 healthy blood donors was collected from the blood bank. The CST1-CTSB detection kit was used to detect the CST1-CTSB concentration in colorectal cancer and normal human serum, and the sample concentration scatter diagram was drawn. It can be seen that CST1-CTSB can statistically distinguish the detection results of serum from colorectal cancer patients and normal people ( Figure 3).
  • the kit provided in this application uses a monoclonal antibody specific for CST1-CTSB as the capture and detection antibody, so that the kit also has the characteristics of high sensitivity, good specificity, low detection limit and good stability. .
  • the linear range of detection can reach 10 ⁇ 1500pg/mL, and the lowest detection limit can reach 5pg/mL.
  • the CST1-CTSB complex itself has the tissue specificity of both CST1 and CTSB proteins, with a specificity of 94.1% and a sensitivity of 87.8% when detecting colorectal cancer samples.
  • the CST1-CTSB detection kit can be used for early diagnosis of colorectal cancer, evaluation of efficacy during treatment, and monitoring of metastasis and recurrence after treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本申请涉及一种半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物作为结肠直肠癌诊断标志物的应用及结肠直肠癌诊断、辅助诊断或预后分析试剂盒。

Description

半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物作为结肠直肠癌诊断标志物的应用
相关申请的交叉引用
本申请要求于2020年10月22日提交中国专利局、申请号为202011136312.7的中国专利申请的优先权，其全部内容通过引用并入本文。
技术领域
本申请涉及医学诊断学领域，具体而言，涉及一种半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物作为结肠直肠癌诊断标志物的应用。
背景技术
结肠直肠癌(colorectal carcer,CRC)是胃肠道中常见的恶性肿瘤之一。
肿瘤发生是多因素、多阶段的过程，肿瘤侵袭转移包括粘附、降解和穿透。肿瘤的侵袭和转移是恶性肿瘤的重要特征。研究认为，蛋白水解酶在肿瘤侵袭过程中有关键作用。蛋白水解酶是一类能够水解或修饰蛋白质或多肽肽键的内肽酶或外肽酶。
组织蛋白酶B(Cathepsin B,CTSB)是存在于哺乳类动物和人体细胞溶酶体中的一种半胱氨酸蛋白酶。最新研究表明，肿瘤组织中CTSB常出现异常表达升高，如胃癌、肠癌、宫颈癌、肺癌、乳腺癌和前列腺癌等。
半胱氨酸蛋白酶抑制剂SN(cystatins SN，CST1)是组织蛋白酶抑制剂的一种，由CST1基因编码的含141个氨基酸的蛋白质，分子量为16.4kDa。CST1分子中含有两个二硫键，为典型的分泌蛋白，它能抑制细胞内、外的组织蛋白酶活 性，在肿瘤的生长、血管生成、浸润和转移中起重要作用，并且有研究表明CST1的高表达与多种癌症相关。
由于CTSB不仅仅在结肠直肠癌中有高表达，在胃癌、神经胶质瘤、黑色素瘤等患者中也存在表达，CTSB用作肿瘤诊断标志物时组织特异性较差，很难用来确定肿瘤的具体类型。虽然CST1在结肠直肠癌中也有一定的区分度，但是由于其序列上与同家族的半胱氨酸蛋白酶抑制剂之间存在高度同源性，因此CST1作为结肠直肠癌靶标也具有一定的局限性。研究表明CTSB是CST1的主要抑制底物之一，CTSB可被CST1抑制而结合形成复合物。
发明内容
根据本申请的各种实施方式，提供了半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物的定量检测剂在制备用于结肠直肠癌的诊断、辅助诊断或预后分析的试剂盒中的应用。
根据本申请的各种实施方式，还提供了一种用于结肠直肠癌的诊断、辅助诊断或预后分析的半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物的定量检测剂。
在一些实施方式中，所述定量检测剂为所述半胱氨酸蛋白酶抑制剂SN以及所述Cathepsin B的特异性抗体，所述抗体可用于执行免疫共沉淀或酶联免疫吸附试验以对所述半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物进行检测。
在一些实施方式中，所述定量检测剂为所述半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物的特异性抗体。
在一些实施方式中，所述特异性抗体为单克隆抗体或多克隆抗体。
在一些实施方式中，所述特异性抗体由SEQ ID NO:1所示的氨基酸序列免疫 得到。
在一些实施方式中，所述特异性抗体具有用于指示信号强度的标记。
在一些实施方式中，所述用于指示信号强度的标记选自发色团、地高辛标记探针、电子致密物质、胶体金或酶中的任一种或多种。
根据本申请的各种实施方式，还提供了结肠直肠癌诊断、辅助诊断或预后分析试剂盒，其包含如上所定义的特异性抗体。
在一些实施方式中，所述试剂盒还包含固相载体、封闭液、显色剂、半胱氨酸蛋白酶抑制剂SN与Cathepsin B融合抗原的校准品以及洗涤缓冲液中的至少一种。
在一些实施方式中，所述固相载体为化学发光板。
根据本申请的各种实施方式，还提供了一种结肠直肠癌的诊断、辅助诊断或预后分析的方法，所述方法包括：使用如上所述的定量检测剂或试剂盒测量半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物的含量。
附图说明
为了更清楚地说明本申请具体实施方式或现有技术中的技术方案，下面将对具体实施方式或现有技术描述中所需要使用的附图作简单地介绍，显而易见地，下面描述中的附图是本申请的一些实施方式，对于本领域普通技术人员来讲，在不付出创造性劳动的前提下，还可以根据这些附图获得其他的附图。
图1为本申请的一种实施方式中CST1-CTSB重组蛋白纯化后的SDS-PAGE电泳图；
图2为本申请的一种实施方式中CST1-CTSB检测试剂盒校准曲线；
图3为本申请的一种实施方式中CST1-CTSB对结肠直肠癌和正常人检测结果的样本浓度散点图；
图4为本申请的一种实施方式中CST1-CTSB对结肠直肠癌诊断的ROC曲线。
具体实施方式
现将详细地提供本申请实施方式的参考，其一个或多个实例描述于下文。提供每一实例作为解释而非限制本申请。实际上，对本领域技术人员而言，显而易见的是，可以对本申请进行多种修改和变化而不背离本申请的范围或精神。例如，作为一个实施方式的部分而说明或描述的特征可以用于另一实施方式中，来产生更进一步的实施方式。
因此，旨在本申请覆盖落入所附权利要求的范围及其等同范围中的此类修改和变化。本申请的其它对象、特征和方面公开于以下详细描述中或从中是显而易见的。本领域普通技术人员应理解本讨论仅是示例性实施方式的描述，而非意在限制本申请更广阔的方面。
本申请涉及半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物(CST1-CTSB复合物)的定量检测剂在制备用于结肠直肠癌的诊断、辅助诊断或预后分析的试剂盒中的应用。
结肠癌和直肠癌统称为结肠直肠癌。两者有许多相似的特征，因此在本申请中将其统一作为一种癌症类型讨论。
本申请提供了一种用于诊断的新标志物：CST1-CTSB复合物。据文献报道，CTSB可被CST1抑制而结合形成复合物，而CST4不具备此能力。因此通过 CST1-CTSB复合物的检测能够有效的提高标志物的组织特异性，还能够有效提高对早期结肠直肠癌的检测率。
本文使用的术语“标志物”指要用作分析患者实验样品的靶标的分子。这样的分子靶标的实例是蛋白或多肽。在本申请中用作标志物的蛋白或多肽预期包括所述蛋白的天然存在的变体以及所述蛋白或所述变体的片段，特别是免疫学上可检测的片段。在一些实施方式中，免疫学上可检测的片段包含所述标志物多肽的至少5、6、7、8、9、10、11、12、15或20个连续氨基酸。本领域的技术人员可认识到，由细胞释放的蛋白或存在于胞外基质中的蛋白可能受到损害(例如，在炎症过程中)，且可被降解或切割成这样的片段。某些标志物以无活性形式合成，其可以随后通过蛋白酶解来激活。如熟练的技术人员将明白的，蛋白或其片段也可以作为复合物的部分而存在。这样的复合物也可以用作本申请意义上的标志物。另外，或在替代方案中，标志物多肽或其变体可以携带翻译后修饰。翻译后修饰的非限制性实例是糖基化、酰化和/或磷酸化。特别地，所述标志物应当位于CST1-CTSB复合物中CST1和CTSB结合部位，这种“结合部位”是指CST1和CTSB相互作用时氨基酸序列互相接触的部位，可以是线性表位或空间表位。
在一些实施方式中，所述定量检测试剂为所述半胱氨酸蛋白酶抑制剂SN以及所述Cathepsin B的特异性抗体，所述抗体可用于执行免疫共沉淀或酶联免疫吸附试验以对所述CST1-CTSB复合物进行检测。
定量检测试剂对CST1-CTSB复合物的检测可采用本领域公知的方法；可尝试的方法例如生物质谱法、非变性聚丙烯酰胺凝胶电泳、色谱法、酶联免疫吸附试验、免疫荧光法、免疫化学发光法、免疫比浊法、免疫印迹法以及斑点印迹。常见的方法为免疫共沉淀以及酶联免疫吸附试验，可通过A抗体捕获CST1，并 洗去未结合的组分，再通过带有信号物质的B抗体检测CTSB；当然也可以捕获CTSB再检测CST1，这对本领域技术人员来说是容易的。
定量检测剂通常是特异性地检测CST1-CTSB复合物的试剂，例如，特异性结合CST1-CTSB复合物的凝集素、特异性结合CST1-CTSB复合物的适配体或特异性结合CST1-CTSB复合物的抗体及抗体片段。特异性的结合剂对其相应的靶分子具有至少10 7l/mol的亲和力。在一些实施方式中，特异性的结合剂对其靶分子可以具有10 8l/mol的亲和力。在一些实施方式中，特异性的结合剂对其靶分子可以具有10 9l/mol的亲和力。技术人员将理解，术语“特异性的”表示，样品中存在的其它生物分子不与CST1-CTSB复合物的定量检测剂发生显著的结合，这样的生物分子特别为单独游离的CST1和CTSB。
在一些实施方式中，所述定量检测剂为CST1-CTSB复合物的特异性抗体。
在一些实施方式中，所述特异性抗体为单克隆抗体或多克隆抗体。
在一些实施方式中，所述特异性抗体由SEQ ID NO:1所示的氨基酸序列免疫得到。
抗体免疫后可经过筛选过程，如本领域技术人员所容易想到的，可通过CST1-CTSB重组蛋白筛选特异性结合CST1-CTSB复合物的抗体，任选的还包括挑选抗体效价高的抗体。
在一些实施方式中，所述特异性抗体具有用于指示信号强度的标记。
在一些实施方式中，所述用于指示信号强度的标记选自发色团、地高辛标记探针、电子致密物质、胶体金或酶中的任一种或多种。
下面非限定部分列出这些标记：
·产生可检测信号的酶，如通过比色法、荧光和发光来检测，如辣根过氧化 物酶，碱性磷酸酶，β-半乳糖苷酶和葡萄糖-6-磷酸脱氢酶。
·发色团，如荧光团、量子点、荧光微球、发光化合物(如吖啶酯或其衍生物)和染料。
·具有能被电子显微镜或通过其电特性，如传导性、电流分析、电压测量和电阻等检测的电子密度的基团。
·可检测基团，如其分子大小足以诱导在其物理和/或化学特性上可检测的修饰；这种检测可通过光学方法(如衍射、表面胞质团共振，表面变异和接触变异角度)或物理方法(如原子力谱学和隧道效应)实现。
·电子致密物质，如放射性分子(如 32P， 35S或 125I)。
根据本申请的再一方面，本申请还涉及结肠直肠癌诊断试剂盒，其包含如上所述定义的特异性抗体。
在一些实施方式中，所述的试剂盒还包含固相载体、封闭液、显色剂、CST1-CTSB融合抗原的校准品以及洗涤缓冲液中的至少一种。
CST1-CTSB融合抗原的校准品优选具有SEQ ID NO:1所示的氨基酸序列。
封闭液可以为BSA、牛血清、脱脂牛奶、TBST等成分中的一种或多种。
显色液可根据抗体上标记的物质进行确定，例如当标记的物质为辣根过氧化物酶时，显色剂可以为鲁米诺。
洗涤缓冲液可为PBS、TBS等成分。
其中，封闭液、显色液、洗涤缓冲液可以工作浓度的形式包装于试剂盒中，也可以它们的浓缩母液的形式被包装(例如2、3、4、5、6、7、8、9、10、20、30、40、50倍浓缩的母液)。
固相载体通常用于包被抗体，用于包被抗体的固相载体物质可为聚苯乙烯、 纤维素、聚丙烯酰胺、聚乙烯聚丙烯、交联葡聚糖、玻璃、硅橡胶、琼脂糖凝胶等材质，载体的形式可以是试管、Eppendorf管、多孔板(特别是化学发光板)、微量反应板凹孔、小珠(特别是磁珠)、小圆片等。
在一些实施方式中，固相载体为化学发光板。其含有的孔数可以为16、32、48、64、96或更多。
根据本申请的再一方面，本申请还提供了一种用于结肠直肠癌的诊断、辅助诊断或预后分析的方法，所述方法包括：使用如上所述的定量检测剂/试剂盒测量CST1-CTSB复合物的含量。
检测的样本可以为受试者的血液、血清、脑脊髓液、组织或组织裂解液、精液以及唾液样品中的至少一种。
受试者通常为哺乳动物。在一些实施方式中，受试者可以为灵长类动物。在一些实施方式中，受试者可以为人。
下面将结合实施例对本申请的实施方案进行详细描述。
实施例1 CST1-CTSB重组蛋白的表达和纯化
蛋白表达：按照序列表SEQ ID NO：1的氨基酸序列合成基因并优化为哺乳动物表达密码子。将基因插入到含有6×His标签的pcDNA3.1载体上，得pcDNA3.1-CST1-CTSB。然后将pcDNA3.1-CST1-CTSB转化至DH5α，挑取阳性克隆并大量培养后，用高纯度质粒提取试剂盒提取重组质粒pcDNA3.1-CST1-CTSB。重组质粒转入293t细胞中，并同时转染pcDNA3.1空载体作为阴性对照，分别在含10％胎牛血清的DMEM培养基在37℃、5％CO 2条件下培养72h，收集上清，利用0.22μm滤膜过滤上清液。
SEQ ID NO:1：
Figure PCTCN2021124691-appb-000001
蛋白纯化：将所得500mL滤液进行非变性条件下的Ni-NTA亲和层析。用平衡缓冲液(50mM PBS、10mM咪唑、150mM NaCl，pH 7.6)进行平衡。上样完毕后，用10mL清洗缓冲液清洗；用洗脱缓冲液(50mM PBS、250mM咪唑、150mM NaCl，pH7.6)洗脱，收集洗脱液。利用3kD超滤管浓缩蛋白溶液，将蛋白保存于50mM PBS缓冲液(pH 7.4)中，-80℃保存。纯化的蛋白通过SDS-PAGE进行纯度鉴定，分子量大小在52kD左右，灰度分析表明蛋白纯度达到95％以上(图1)。
实施例2 CST1-CTSB重组蛋白的活性验证和抗体配对
活性分析：以1μg/ml的重组CST1-CTSB蛋白的碳酸盐缓冲液(pH9.5)，每孔100μl体积4℃过夜包被化学发光板。将捕获抗体和检测抗体分别梯度稀释(浓 度为0～1μg/ml)并分别添加到板中进行孵育，洗涤后加入辣根过氧化物酶(HRP)标记的羊抗鼠IgG(100ng/ml)并孵育，洗涤后进行检测。检测发现捕获抗体和检测抗体在100ng/ml时的发光值均不低于20万，蛋白与抗体的反应曲线R 2大于0.99，蛋白的反应活性满足要求。
抗体配对：以1μg/ml捕获抗体包被化学发光板。每孔加入100μl不同浓度(5～1000pg/mL)的CST1-CTSB校准品，37℃孵育60min，洗涤后每孔加入100μL浓度为100ng/ml的HRP标记的检测抗体，并于37℃孵育60min，洗涤后加入化学发光底物并测定各孔发光强度。从结果上看，捕获抗体和检测抗体配对良好，可用于双抗夹心体系构建。
实施例3 CST1-CTSB校准曲线绘制
校准曲线绘制：首先在化学发光板上4℃过夜包被捕获抗体，浓度为1μg/mL。将重组人CST1-CTSB校准品蛋白用蛋白质稳定剂稀释为0pg/mL、10pg/mL、50pg/mL、100pg/mL、200pg/mL、500pg/mL、1500pg/mL，每孔加入100μL，进行孵育，洗涤后加入HRP标记的检测抗体，浓度5ng/ml，每孔100μL，37℃孵育1小时。用PBST清洗3次，加入化学发光底物并测定各孔发光强度，然后绘制校准曲线。从校准曲线可以计算出被测样品的CST1-CTSB含量。图2为CST1-CTSB检测试剂盒校准曲线，校准曲线线性范围10～1500pg/mL，其中，Y轴代表发光值对数值，X轴代表CST1-CTSB校准品的浓度对数值。
实施例4、CST1-CTSB试剂盒临床性能验证
CST1-CTSB检测试剂盒用于结肠直肠癌诊断。从医院收集结肠直肠癌患者术前血清各50例；同时从血站收集50例健康献血人员血清。使用CST1-CTSB 检测试剂盒检测结肠直肠癌、正常人血清中CST1-CTSB浓度，并绘制样本浓度散点图。可见，CST1-CTSB能够有统计学意义地对结肠直肠癌患者和正常人的血清的检测结果进行区分(图3)。ROC曲线统计结果显示，曲线下面积为0.93，以91.18pg/mL作为检测参考值，CST1-CTSB检测试剂盒特异性为94.1％，灵敏度为87.8％(图4)。
综上所述，本申请所提供的试剂盒采用特异性针对CST1-CTSB的单克隆抗体作为捕获和检测抗体，使得试剂盒还具有灵敏度高、特异性好、检测限低及稳定性好等特性。检测的线性范围达到10～1500pg/mL，最低检测限可达5pg/mL。CST1-CTSB复合物本身兼具CST1和CTSB蛋白的组织特异性，在检测结肠直肠癌样本时，特异性94.1％，灵敏度可达到87.8％。CST1-CTSB检测试剂盒能够用于结肠直肠癌的早期诊断、治疗过程中的疗效评估以及治疗后的转移复发监控。
以上所述实施例的各技术特征可以进行任意的组合，为使描述简洁，未对上述实施例中的各个技术特征所有可能的组合都进行描述，然而，只要这些技术特征的组合不存在矛盾，都应当认为是本说明书记载的范围。
以上所述实施例仅表达了本申请的几种实施方式，其描述较为具体和详细，但并不能因此而理解为对发明专利范围的限制。应当指出的是，对于本领域的普通技术人员来说，在不脱离本申请构思的前提下，还可以做出若干变形和改进，这些都属于本申请的保护范围。因此，本申请专利的保护范围应以所附权利要求为准。

Claims (24)

  1. 半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物(CST1-CTSB复合物)的定量检测剂在制备用于结肠直肠癌的诊断、辅助诊断或预后分析的试剂盒中的应用。
  2. 根据权利要求1所述的应用，其中，所述定量检测剂为所述半胱氨酸蛋白酶抑制剂SN以及所述Cathepsin B的特异性抗体，所述抗体可用于执行免疫共沉淀或酶联免疫吸附试验以对所述半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物复合物进行检测。
  3. 根据权利要求1所述的应用，其中，所述定量检测剂为所述CST1-CTSB复合物的特异性抗体。
  4. 根据权利要求3所述的应用，其中，所述特异性抗体为单克隆抗体或多克隆抗体。
  5. 根据权利要求4所述的应用，其中，所述特异性抗体由SEQ ID NO:1所示的氨基酸序列免疫得到。
  6. 根据权利要求3～5任一项所述的应用，其中，所述特异性抗体具有用于指示信号强度的标记。
  7. 根据权利要求6所述的应用，其中，所述用于指示信号强度的标记选自发色团、地高辛标记探针、电子致密物质、胶体金或酶中的任一种或多种。
  8. 一种用于结肠直肠癌的诊断、辅助诊断或预后分析的半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物的定量检测剂。
  9. 根据权利要求8所述的定量检测剂，其中，所述定量检测剂为所述半胱氨酸蛋白酶抑制剂SN以及所述Cathepsin B的特异性抗体，所述抗体可用于执行免 疫共沉淀或酶联免疫吸附试验以对所述半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物进行检测。
  10. 根据权利要求8所述的定量检测剂，其中，所述定量检测剂为所述半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物的特异性抗体。
  11. 根据权利要求10所述的定量检测剂，其中，所述特异性抗体为单克隆抗体或多克隆抗体。
  12. 根据权利要求11所述的定量检测剂，其中，所述特异性抗体由SEQ ID NO:1所示的氨基酸序列免疫得到。
  13. 根据权利要求10～12中任一项所述的定量检测剂，其中，所述特异性抗体具有用于指示信号强度的标记。
  14. 根据权利要求13所述的定量检测剂，其中，所述用于指示信号强度的标记选自发色团、地高辛标记探针、电子致密物质、胶体金或酶中的任一种或多种。
  15. 结肠直肠癌诊断、辅助诊断或预后分析试剂盒，其中其中，包含权利要求3～7任一项中所定义的特异性抗体。
  16. 根据权利要求15所述的试剂盒，其中，还包含固相载体、封闭液、显色剂、半胱氨酸蛋白酶抑制剂SN与Cathepsin B融合抗原的校准品以及洗涤缓冲液中的至少一种。
  17. 根据权利要求16所述的试剂盒，其中，所述固相载体为化学发光板。
  18. 一种结肠直肠癌的诊断、辅助诊断或预后分析的方法，所述方法包括：使用根据权利要求8所述的定量检测剂或根据权利要求15所述的试剂盒测量半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物的含量。
  19. 根据权利要求18所述的方法，其中，所述定量检测剂为所述半胱氨酸蛋 白酶抑制剂SN以及所述Cathepsin B的特异性抗体，所述抗体可用于执行免疫共沉淀或酶联免疫吸附试验以对所述半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物进行检测。
  20. 根据权利要求19所述的方法，其中，所述定量检测剂为所述半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物的特异性抗体。
  21. 根据权利要求20所述的方法，其中，所述特异性抗体为单克隆抗体或多克隆抗体。
  22. 根据权利要求21所述的方法，其中，所述特异性抗体由SEQ ID NO:1所示的氨基酸序列免疫得到。
  23. 根据权利要求20～22中任一项所述的方法，其中，所述特异性抗体具有用于指示信号强度的标记。
  24. 根据权利要求23所述的方法，其中，所述用于指示信号强度的标记选自发色团、地高辛标记探针、电子致密物质、胶体金或酶中的任一种或多种。
PCT/CN2021/124691 2020-10-22 2021-10-19 半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物作为结肠直肠癌诊断标志物的应用 WO2022083582A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011136312.7A CN112379097B (zh) 2020-10-22 2020-10-22 Cst1-ctsb复合物作为结肠直肠癌诊断标志物的应用
CN202011136312.7 2020-10-22

Publications (1)

Publication Number Publication Date
WO2022083582A1 true WO2022083582A1 (zh) 2022-04-28

Family

ID=74580539

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/124691 WO2022083582A1 (zh) 2020-10-22 2021-10-19 半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物作为结肠直肠癌诊断标志物的应用

Country Status (2)

Country Link
CN (1) CN112379097B (zh)
WO (1) WO2022083582A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112379097B (zh) * 2020-10-22 2022-07-26 上海良润生物医药科技有限公司 Cst1-ctsb复合物作为结肠直肠癌诊断标志物的应用
CN112379093B (zh) * 2020-10-22 2023-06-16 上海良润生物医药科技有限公司 CST-Cathepsin复合物作为肿瘤诊断标志物的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101985651A (zh) * 2010-04-30 2011-03-16 苏州工业园区为真生物医药科技有限公司 胃肠肿瘤诊断和预示的新分子标记
CN107367615A (zh) * 2016-05-11 2017-11-21 优势医疗有限责任公司 检测癌症的方法和试剂盒
CN112379093A (zh) * 2020-10-22 2021-02-19 上海良润生物医药科技有限公司 CST-Cathepsin复合物作为肿瘤诊断标志物的应用
CN112379097A (zh) * 2020-10-22 2021-02-19 上海良润生物医药科技有限公司 Cst1-ctsb复合物作为结肠直肠癌诊断标志物的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120053080A1 (en) * 2009-03-09 2012-03-01 Juan Cui Protein markers identification for gastric cancer diagnosis
JP6192122B2 (ja) * 2012-01-09 2017-09-06 スージョウ マイクロダイアグ バイオメディスン カンパニー リミテッド 結腸直腸癌診断および予測のためのバイオマーカー
CN107688095A (zh) * 2017-08-19 2018-02-13 杭州飞悦生物技术有限公司 检测人胱抑素sn的酶联免疫试剂盒及制备方法及检测方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101985651A (zh) * 2010-04-30 2011-03-16 苏州工业园区为真生物医药科技有限公司 胃肠肿瘤诊断和预示的新分子标记
CN107367615A (zh) * 2016-05-11 2017-11-21 优势医疗有限责任公司 检测癌症的方法和试剂盒
CN112379093A (zh) * 2020-10-22 2021-02-19 上海良润生物医药科技有限公司 CST-Cathepsin复合物作为肿瘤诊断标志物的应用
CN112379097A (zh) * 2020-10-22 2021-02-19 上海良润生物医药科技有限公司 Cst1-ctsb复合物作为结肠直肠癌诊断标志物的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LI TAIYUAN, XIONG QIANGQIANG, ZOU ZHEN, LEI XIONG, JIANG QUNGUANG, LIU DONGNING: "Prognostic significance of cystatin SN associated nomograms in patients with colorectal cancer", ONCOTARGET, vol. 8, no. 70, 29 December 2017 (2017-12-29), pages 115153 - 115163, XP055923842, DOI: 10.18632/oncotarget.23041 *
ZORE I, ET AL.: "CATHEPSIN B/CYSTATIN C COMPLEX LEVELS IN SERA FROM PATIENTS WITH LUNG AND COLORECTAL CANCER", BIOLOGICAL CHEMISTRY, WALTER DE GRUYTER GMBH & CO., BERLIN, DE, vol. 382, no. 05, 1 May 2001 (2001-05-01), BERLIN, DE , pages 805 - 810, XP001107112, ISSN: 1431-6730, DOI: 10.1515/BC.2001.097 *

Also Published As

Publication number Publication date
CN112379097A (zh) 2021-02-19
CN112379097B (zh) 2022-07-26

Similar Documents

Publication Publication Date Title
WO2022083586A1 (zh) 半胱氨酸蛋白酶抑制剂sn与cathepsin l1复合物作为胃癌诊断标志物的应用
WO2022083603A1 (zh) 半胱氨酸蛋白酶抑制剂与Cathepsin复合物作为肿瘤诊断标志物的应用
WO2022083582A1 (zh) 半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物作为结肠直肠癌诊断标志物的应用
US8288110B2 (en) Biomarkers for detecting cancer
JP2009527735A (ja) 癌に対するバイオマーカーとしての遊離ｎｇａｌ
WO2022063156A1 (zh) 乳腺癌的生物标志物及其应用
JP5731488B2 (ja) 癌のマーカーとしてのセセルニン‐１
WO2022083580A1 (zh) 半胱氨酸蛋白酶抑制剂SN与Cathepsin H复合物作为食管癌诊断标志物的应用
WO2010032458A1 (ja) 新規非アルコール性脂肪性肝疾患バイオマーカーおよび該バイオマーカーを用いた非アルコール性脂肪性肝疾患の検出方法
US20170138958A1 (en) Method for measuring anti-wt1 antibody
US20220236275A1 (en) Cancer test method
KR20120116518A (ko) 폐암 조기 진단용 ＸＡＧＥ-1ａ 마커 및 이의 용도
CN111656196A (zh) 肾癌的检测方法和检查试剂
US11193944B2 (en) Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof
JP5653725B2 (ja) 筋萎縮性側索硬化症マーカー及びその利用
US8252542B2 (en) Serpin B 13 as a marker for squamous cell carcinoma of the lung
WO2021246153A1 (ja) 膵臓がんの検出方法及び検出試薬
WO2021261483A1 (ja) 腺癌の検出方法及び検査キット
WO2005094422A2 (en) Angiocidin fragments and uses thereof in clinical assays for cancer and other diseases
CA2702623A1 (en) Use of tenascin-w as a biomarker for colon cancer
WO2021172000A1 (ja) 卵巣悪性腫瘍の検出方法及び検出試薬
KR20110115292A (ko) 폐암 진단용 Ｘａｇｅ－１ｄ 마커 및 이를 이용한 진단 키트
KR101652894B1 (ko) 대장암에 대한 신규 바이오마커 및 그의 용도
KR20220017101A (ko) 자가면역 뇌염의 진단 방법
CA2852757A1 (en) Predictive biomarkers for breast cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21881998

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21881998

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 21881998

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC